EHA 2024: Updates in the Treatment of CLL

Catherine C. Coombs, MD, Matthew S. Davids, MD, MMSc; Richardo D. Parrondo, MD; Nicole Lamanna, MD, and Alexey Danilov, MD, PhD, examine treatment approaches for newly diagnosed chronic lymphocytic leukemia (CLL), including BTK inhibitor therapy, management of adverse events, and strategies for relapsed/refractory CLL.

EP. 1: Introducing the Expert Panel on CLL Treatment Updates Live at EHA 2024

June 27th 2024

Key opinion leaders are introduced and present a concise overview of the topics to be addressed.

EP. 2: Testing Practices and Role of High-risk Features to Decision Making in Newly Diagnosed CLL

June 27th 2024

Leading chronic lymphocytic leukemia specialists explore strategies for selecting initial treatments, weighing the merits of fixed-duration versus continuous Bruton's tyrosine kinase inhibitor (BTKi) therapy for newly diagnosed patients.

EP. 3: Frontline BTKi Selection

July 8th 2024

Key opinion leaders examine the use of continuous Bruton's tyrosine kinase inhibitor therapy in front-line treatment, strategies for sequencing therapies, and the potential incorporation of obinutuzumab into treatment regimens.

EP. 4: Dr Parrondo’s Frontline CLL Treatment Approach for Pre-existing HTN and Afib

July 8th 2024

The panelists explore strategies for managing front-line chronic lymphocytic leukemia (CLL) treatment in patients with pre-existing hypertension and atrial fibrillation.

EP. 5: Dr Lamanna Reviews Study Data for 1L Doublet Therapy or Triplet Therapy

July 15th 2024

A chronic lymphocytic leukemia expert examines patient criteria for first-line doublet therapy (venetoclax plus BTK inhibitor) versus triplet therapy, while also addressing findings from the CAPTIVATE trial.

EP. 6: Dr Danilov Reviews EHA 2024 Data on the Role of 1L Triplet Therapy in CLL

July 15th 2024

Experts analyze the potential applications of triplet therapy (venetoclax, BTK inhibitor, and obinutuzumab) in first-line chronic lymphocytic leukemia treatment, focusing on patient subgroups most likely to benefit from this approach.

EP. 7: EHA 2024 Review of Ongoing Trials Evaluating BCL2i/BTKi Combination Approaches

July 22nd 2024

An expert in the field provides insights into current clinical trials investigating the efficacy of combined BCL-2 inhibitor and BTK inhibitor therapies.

EP. 8: Navigating Treatment Approaches for R/R CLL

July 22nd 2024

A clinician outlines their treatment strategy for relapsed/refractory chronic lymphocytic leukemia patients, emphasizing how previous treatment history influences subsequent therapy choices.

EP. 9: How Experts View MAIC Data That was Presented at EHA 2024

July 29th 2024

A panel of experts examines and interprets the most recent matching-adjusted indirect comparison (MAIC) data presented at the European Hematology Association 2024 conference, focusing on the comparative analysis of the ASCEND and ALPINE trials in chronic lymphocytic leukemia treatment.

EP. 10: BTKi Intolerance in Real-world Practice & Management Strategy

July 29th 2024

Key opinion leaders compare and contrast the most frequently observed causes of BTK inhibitor intolerance in clinical practice among patients treated with ibrutinib, acalabrutinib, or zanubrutinib.

EP. 11: Applying EHA 2024 Data to Switching and Sequencing Treatments for CLL & Impact of Toxicities

August 5th 2024

Experts analyze recent real-world evidence on treatment patterns, focusing on the strategies and outcomes of switching and sequencing therapies in chronic lymphocytic leukemia patients.

EP. 12: Approach to Hypertension Management With BTKi Treatment

August 5th 2024

Medical experts deliberate on strategies for managing newly developed or exacerbated hypertension in patients undergoing treatment with BTK inhibitors for chronic lymphocytic leukemia.

EP. 13: Dr Parrondo shares Approach to Managing BTKi Treatment-Related Afib

August 12th 2024

An oncology specialist outlines their general approach to managing treatment-related atrial fibrillation in patients receiving BTK inhibitor therapy, incorporating insights from recent clinical data to inform their management strategies.

EP. 14: Navigating BTKi Resistance in CLL with Findings from ELEVATE-RR and ALPINE Studies: Sequencing Approach and Potential Role for Testing

August 12th 2024

Key opinion leaders examine recent evidence on acquired BTK inhibitor resistance in chronic lymphocytic leukemia and analyze its implications for treatment sequencing decisions in clinical practice.